Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations
RUET, Aurélie
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
< Reduce
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
Language
EN
Article de revue
This item was published in
Revue Neurologique. 2024-10, vol. 180, n° 8, p. 711-714
English Keywords
Aquaporin 4
Cost-Benefit Analysis
France
Humans
Immunologic Factors
Neuromyelitis Optica
Rituximab
Treatment Outcome
Collections